<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005925</url>
  </required_header>
  <id_info>
    <org_study_id>000158</org_study_id>
    <secondary_id>00-N-0158</secondary_id>
    <nct_id>NCT00005925</nct_id>
  </id_info>
  <brief_title>Brain Infusion of Muscimol to Treat Epilepsy</brief_title>
  <official_title>Trial of Intracerebral Infusion in Patients With Medically Intractable Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will examine the safety and effectiveness of infusing a chemical called muscimol
      into the brain to control seizures in patients with intractable epilepsy (frequent seizures
      that persist despite therapy). Muscimol, which is similar to a naturally occurring brain
      chemical called GABA, has been shown to reduce seizures in rats. After the infusion study,
      patients will undergo a standard surgical procedure for controlling seizures.

      Patients 18 years of age or older with intractable epilepsy may be eligible for this study.
      Before entering protocol 00-N-0158, candidates will be screened under protocol 01-N-0139,
      Evaluation and Treatment of Patients with Epilepsy, with a medical history, physical and
      neurologic examination, chest X-ray, electrocardiogram, blood and urine tests,
      electroencephalographic (EEG) monitoring and magnetic resonance imaging (MRI) of the head.

      Patients enrolled in this study will have the following procedures:

        1. Computerized tomography (CT) and magnetic resonance imaging (MRI) of the head to guide
           catheter/electrode placement (see #2).

        2. Depth catheter/electrode placement into the presumed location of the seizure focus (the
           part of the brain where the seizures originate) - A small hole is drilled through the
           skull. A depth electrode with a hole in the center of the tubing is passed through the
           brain into the structures usually involved in intractable epilepsy. MRI will be done to
           check electrode placement. Video-EEG monitoring will continue for 5 days for this part
           of the study. Patients will be tested for their ability to understand and produce
           speech, see normally, move their arms and legs, distinguish sharp and dull objects, and
           put pegs in a pegboard. They will be questioned about headache, weakness, numbness or
           sleepiness. The electrode will be left in place for muscimol infusion (see #3).

        3. Muscimol infusion - Into the seizure focus, patients will be given two infusions-one of
           saline (salt water) alone and one of muscimol diluted in saline. Each infusion will be
           given over a period of one-half to 5 1/2 days, infused at the rate of 0.1 ml (1/50th of
           a teaspoon) per hour. During the infusions video-EEG recordings will continue and
           patients will be interviewed and examined as described in #2 above).

        4. Blood testing - About 2 tablespoons of blood will be drawn daily during the testing
           period and for the first 2 days after surgery (see #5).

        5. Surgery - Temporal lobectomy or topectomy (removal of a small, specific area of brain
           tissue) is the standard surgical treatment for medically intractable epilepsy whose
           seizure focus is not in a critical brain region, such as an area that controls language,
           movement, or sensation. If the patient's seizures arise from one of these areas, an
           alternative procedure called multiple subpial transection will be offered. In this
           procedure, vertical cuts are made in the seizure focus to prevent neurons (nerve cells
           that transmit electrical impulses) in the focus from spreading the seizure to the rest
           of the brain.

        6. Surgery follow-up - Patients will be monitored in the surgical intensive care unit for
           24 to 48 hours and then in the NINDS nursing unit for 4 to 8 days before being
           discharged to home. Another visit in the NINDS outpatient clinic will be scheduled for
           6-12 weeks after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: The objectives of this study are to test the hypotheses that direct infusion of
      the brain (convection enhanced delivery) with neurotransmitter receptor agonists is 1) safe
      and 2) can be used to study the basic pathophysiology of the epileptic focus in human
      subjects. The approach described may be a new approach for precise localization of a seizure
      focus. It may also prove to indicate the distribution of suppression (in space) required for
      elimination of seizure activity in individual patients and, by doing so, may more accurately
      define the minimum treatment area that is required for success. Finally, the data obtained
      may support the treatment of patients with medically intractable epilepsy with
      neurotransmitter-specific agents infused directly into the epileptic focus.

      Study Population: The study population will include adult patients with medically intractable
      epilepsy who are candidates for surgical resection of their epileptic region.

      Design: Adult patients who are candidates for standard surgical care for medically
      intractable epilepsy will undergo standard noninvasive evaluation to identify the location of
      the seizure focus. After surface EEG confirms the side and approximate location of the
      seizure focus, a depth electrode with a central lumen will be placed in the seizure focus for
      the purpose of this research study. The lumen in the depth electrode will be used to deliver
      vehicle (artificial cerebrospinal fluid) or muscimol, a neurotransmitter (gamma-aminobutyric
      acid, GABA) receptor agonist that suppresses neuronal activity. During the infusion trials,
      patients will be monitored by neurologic examination and by video-EEG. Following the trials,
      the epileptic focus will be resected, which is standard care for medically intractable
      epilepsy, and the surgical specimen will be examined for any histological changes caused by
      the infusions.

      Outcome Measures: Basic pathophysiology of the epileptic focus will be examined by assessing
      the effect of the infusion on seizure frequency (the primary end point), EEG recordings,
      motor function, and visual object naming. Safety will be assessed by neurologic examination
      and by pathologic examination (gross and microscopic) of the resected surgical specimen
      (presence or absence of infusion-induced injury).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 23, 2000</start_date>
  <completion_date type="Actual">December 24, 2014</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">3</enrollment>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Muscimol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        To be eligible for entry into the study, candidates must meet all the following criteria:

          1. Be 18 years of age or older.

          2. Have simple or complex partial seizures.

          3. Seizures must persist at 2 or more per month, despite medical therapy.

          4. Be able to give informed consent.

          5. Have been determined by the NIH neurology staff to have medically intractable
             epilepsy.

          6. Have a seizure focus in a single region of one cerebral hemisphere.

        EXCLUSION CRITERIA:

        Candidates will be excluded if they:

          1. Are pregnant.

          2. Have a contraindication to MRI scanning.

          3. Have a bleeding disorder that cannot be corrected before testing or treatment.

          4. Are unable to comprehend the risks of the testing and surgical therapy.

          5. Have seizure foci in more than one region of one hemisphere or in both cerebral
             hemispheres.

          6. Have a positive HIV test, because such patients would have increased risk of infection
             due to their immune deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D Heiss, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sperling MR, Feldman H, Kinman J, Liporace JD, O'Connor MJ. Seizure control and mortality in epilepsy. Ann Neurol. 1999 Jul;46(1):45-50.</citation>
    <PMID>10401779</PMID>
  </reference>
  <reference>
    <citation>Eder HG, Jones DB, Fisher RS. Local perfusion of diazepam attenuates interictal and ictal events in the bicuculline model of epilepsy in rats. Epilepsia. 1997 May;38(5):516-21.</citation>
    <PMID>9184595</PMID>
  </reference>
  <reference>
    <citation>Brailowsky S, Silva-Barrat C, MÃ©nini C, Riche D, Naquet R. Effects of localized, chronic GABA infusions into different cortical areas of the photosensitive baboon, Papio papio. Electroencephalogr Clin Neurophysiol. 1989 Feb;72(2):147-56.</citation>
    <PMID>2464486</PMID>
  </reference>
  <reference>
    <citation>Heiss JD, Walbridge S, Morrison P, Hampton RR, Sato S, Vortmeyer A, Butman JA, O'Malley J, Vidwan P, Dedrick RL, Oldfield EH. Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg. 2005 Dec;103(6):1035-45.</citation>
    <PMID>16381190</PMID>
  </reference>
  <verification_date>December 24, 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2000</study_first_submitted>
  <study_first_submitted_qc>June 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2000</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Video-EEG</keyword>
  <keyword>Muscimol</keyword>
  <keyword>Depth Electrode</keyword>
  <keyword>Brain Catheter</keyword>
  <keyword>Pharmacology</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Infusion</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscimol</mesh_term>
    <mesh_term>Ibotenic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

